{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:54:44Z","timestamp":1768802084706,"version":"3.49.0"},"reference-count":168,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Densitometry"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jocd.2019.09.006","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T11:38:01Z","timestamp":1569584281000},"page":"1-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Proceedings of the 2019 Santa Fe Bone Symposium: New Concepts in the Care of Osteoporosis and Rare Bone Diseases"],"prefix":"10.1016","volume":"23","author":[{"given":"E. Michael","family":"Lewiecki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Kagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Krakow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"McClung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric T.","family":"Rush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Shuhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson B.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine W.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocd.2019.09.006_bib0001","first-page":"825","article-title":"Proceedings of the Santa Fe Bone Symposium 2006","volume":"2","author":"Lewiecki","year":"2006","journal-title":"Womens Health"},{"key":"10.1016\/j.jocd.2019.09.006_bib0002","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jocd.2007.12.017","article-title":"Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3-4, 2007","volume":"11","author":"Lewiecki","year":"2008","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2019.09.006_bib0003","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jocd.2009.02.002","article-title":"2008 Santa Fe Bone Symposium: update on osteoporosis","volume":"12","author":"Lewiecki","year":"2009","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2019.09.006_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jocd.2009.12.003","article-title":"2009 Santa Fe Bone Symposium","volume":"13","author":"Lewiecki","year":"2010","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2019.09.006_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jocd.2010.12.001","article-title":"Osteoporosis update from the 2010 Santa Fe Bone Symposium","volume":"14","author":"Lewiecki","year":"2010","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2019.09.006_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jocd.2011.11.004","article-title":"Proceedings of the 2011 Santa Fe Bone Symposium","volume":"15","author":"Lewiecki","year":"2012","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2019.09.006_bib0007","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jocd.2013.01.001","article-title":"Osteoporosis Update From the 2012 Santa Fe Bone Symposium","volume":"16","author":"Lewiecki","year":"2013","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2019.09.006_bib0008","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jocd.2013.11.006","article-title":"Osteoporosis update: proceedings of the 2013 Santa Fe Bone Symposium","volume":"17","author":"Lewiecki","year":"2014","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2019.09.006_bib0009","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3109\/07435800.2015.1005746","article-title":"Update on osteoporosis from the 2014 Santa Fe Bone Symposium","volume":"40","author":"Lewiecki","year":"2015","journal-title":"Endocr Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0010","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jocd.2015.11.003","article-title":"Proceedings of the 2015 Santa Fe Bone Symposium: clinical applications of scientific advances in osteoporosis and metabolic bone disease","volume":"19","author":"Lewiecki","year":"2016","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2019.09.006_bib0011","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jocd.2017.01.001","article-title":"Proceedings of the 2016 Santa Fe Bone Symposium: new concepts in the management of osteoporosis and metabolic bone diseases","volume":"20","author":"Lewiecki","year":"2017","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2019.09.006_bib0012","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jocd.2017.10.041","article-title":"Proceedings of the 2017 Santa Fe Bone Symposium: insights and emerging concepts in the management of osteoporosis","volume":"21","author":"Lewiecki","year":"2018","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2019.09.006_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jocd.2018.09.010","article-title":"Proceedings of the 2018 Santa Fe Bone Symposium: advances in the management of osteoporosis","volume":"22","author":"Lewiecki","year":"2019","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2019.09.006_bib0014","unstructured":"Lewiecki EM, Bilezikian JP, Miller PD, et al. 2009Highlights from the 2009 Santa Fe Bone Symposium. Available at: http:\/\/www.2009santafebonesymposium.com\/downloads\/2009-Santa-Fe-Bone-Newsletter.pdf. Accessed 8\/25\/2011."},{"key":"10.1016\/j.jocd.2019.09.006_bib0015","unstructured":"Lewiecki EM, Bilezikian JP, Khosla S., et al. 2010Highlights from the 2010 Santa Fe Bone Symposium. Available at: http:\/\/santafebonesymposium.squarespace.com\/storage\/assets\/2010_Santa_Fe_Bone.pdf. Accessed 8\/25\/2011."},{"key":"10.1016\/j.jocd.2019.09.006_bib0016","doi-asserted-by":"crossref","unstructured":"Lewiecki EM, Bilezikian JP, McCloskey EV, et al. 2011Highlights of the 2011 Santa Fe Bone Symposium. Available at: http:\/\/www.2011santafebonesymposium.com\/2011-Santa-Fe-Bone-Newsletter.pdf. Accessed 1\/19\/2012.","DOI":"10.1016\/j.jocd.2011.11.004"},{"key":"10.1016\/j.jocd.2019.09.006_bib0017","unstructured":"Lewiecki EM, Bilezikian JP, Bonewald LF, et al. 20132013 Santa Fe Bone Symposium Highlights. Available at: http:\/\/2013santafebonesymposium.com. Accessed 9\/06\/2015."},{"key":"10.1016\/j.jocd.2019.09.006_bib0018","unstructured":"Lewiecki EM, Bilezikian JP, Binkley N, et al. 20142014 Santa Fe Bone Symposium Highlights. Available at: http:\/\/www.2014santafebonesymposium.com\/. Accessed 9\/6\/2015."},{"key":"10.1016\/j.jocd.2019.09.006_bib0019","unstructured":"Lewiecki EM, Bilezikian JP, Khosla S., et al. 20102010 Santa Fe Bone Symposium. Available at: http:\/\/www.2010santafebonesymposium.com\/. Accessed 8\/25\/2011."},{"key":"10.1016\/j.jocd.2019.09.006_bib0020","unstructured":"Lewiecki EM, Bilezikian JP, Miller PD, et al. 20092009 Santa Fe Bone Symposium. Available at: http:\/\/www.2009santafebonesymposium.com\/. Accessed 8\/25\/2011."},{"key":"10.1016\/j.jocd.2019.09.006_bib0021","doi-asserted-by":"crossref","unstructured":"Lewiecki EM, Bilezikian JP, Jankowski LG, et al. 20112011 Santa Fe Bone Symposium Highlights. Available at: http:\/\/www.2011santafebonesymposium.com\/presentations.html. Accessed 9\/15\/2012.","DOI":"10.1016\/j.jocd.2011.11.004"},{"key":"10.1016\/j.jocd.2019.09.006_bib0022","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0140-6736(17)31430-7","article-title":"Hyperparathyroidism","volume":"391","author":"Bilezikian","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jocd.2019.09.006_bib0023","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1210\/jc.2018-01225","article-title":"Primary hyperparathyroidism","volume":"103","author":"Bilezikian","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2019.09.006_bib0024","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1210\/endo.138.11.5505","article-title":"The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats","volume":"138","author":"Dobnig","year":"1997","journal-title":"Endocrinology"},{"key":"10.1016\/j.jocd.2019.09.006_bib0025","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2019.09.006_bib0026","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-Type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.jocd.2019.09.006_bib0027","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2019.09.006_bib0028","doi-asserted-by":"crossref","DOI":"10.1080\/03007995.2019.1656955","article-title":"Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial","author":"Bilezikian","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jocd.2019.09.006_bib0029","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2019.09.006_bib0030","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0031","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2019.09.006_bib0032","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00198-019-05020-8","article-title":"Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group","volume":"30","author":"Bilezikian","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.09.006_bib0033","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jocd.2017.05.007","article-title":"Effects of teriparatide, denosumab, or both on spine trabecular microarchitecture in DATA-Switch: a randomized controlled trial","volume":"20","author":"Tsai","year":"2017","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2019.09.006_bib0034","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jbmr.2315","article-title":"Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study","volume":"30","author":"Tsai","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0035","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jocd.2019.09.006_bib0036","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1210\/jc.2016-1160","article-title":"Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study)","volume":"101","author":"Tsai","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2019.09.006_bib0037","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jocd.2016.01.004","article-title":"Response to therapy with teriparatide, denosumab, or both in postmenopausal women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial","volume":"19","author":"Leder","year":"2016","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2019.09.006_bib0038","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/jgs.15250","article-title":"Protective effect of denosumab on bone in older women with primary hyperparathyroidism","volume":"66","author":"Eller-Vainicher","year":"2018","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jocd.2019.09.006_bib0039","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00198-019-05002-w","article-title":"Fracture risk following intermission of osteoporosis therapy","volume":"30","author":"Dennison","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.09.006_bib0040","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0041","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bone.2012.11.011","article-title":"The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis","volume":"53","author":"Nelson","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2019.09.006_bib0042","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jbmr.534","article-title":"Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN)","volume":"27","author":"Greendale","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0043","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJM199208273270908","article-title":"The prevention and treatment of osteoporosis","volume":"327","author":"Riggs","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2019.09.006_bib0044","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1056\/NEJMcp1513724","article-title":"Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2019.09.006_bib0045","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/GME.0000000000001124","article-title":"Hormone therapy for the treatment of postmenopausal osteoporosis: will it soon become a lost art in medicine?","volume":"25","author":"Jiang","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.jocd.2019.09.006_bib0046","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2019.09.006_bib0047","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00198-018-4414-z","article-title":"Estrogen therapy for osteoporosis in the modern era","volume":"29","author":"Levin","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.09.006_bib0048","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2019.09.006_bib0049","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2019.09.006_bib0050","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1359\/jbmr.060312","article-title":"Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial","volume":"21","author":"Jackson","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0051","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jocd.2019.09.006_bib0052","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2019.09.006_bib0053","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/GME.0000000000000921","article-title":"The 2017 hormone therapy position statement of The North American Menopause Society","volume":"24","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.jocd.2019.09.006_bib0054","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2019.09.006_bib0055","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.amjmed.2009.05.021","article-title":"Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women","volume":"122","author":"Salpeter","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.jocd.2019.09.006_bib0056","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause","volume":"297","author":"Rossouw","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2019.09.006_bib0057","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/jama.2017.11217","article-title":"Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative Randomized Trials","volume":"318","author":"Manson","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2019.09.006_bib0058","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/AOG.0b013e31827a08c8","article-title":"Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy","volume":"121","author":"Rossouw","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jocd.2019.09.006_bib0059","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1001\/jama.2019.5346","article-title":"Menopausal hormone therapy","volume":"321","author":"Shifren","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2019.09.006_bib0060","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13697137.2015.1129166","article-title":"2016 IMS Recommendations on women's midlife health and menopause hormone therapy","volume":"19","author":"Baber","year":"2016","journal-title":"Climacteric"},{"key":"10.1016\/j.jocd.2019.09.006_bib0061","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/GME.0000000000000175","article-title":"Extended duration use of menopausal hormone therapy","volume":"21","author":"Kaunitz","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.jocd.2019.09.006_bib0062","first-page":"302","article-title":"No increase in fractures after stopping hormone therapy: results from the Women's Health Initiative","volume":"102","author":"Watts","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2019.09.006_bib0063","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.clp.2015.03.003","article-title":"Skeletal dysplasias","volume":"42","author":"Krakow","year":"2015","journal-title":"Clin Perinatol"},{"key":"10.1016\/j.jocd.2019.09.006_bib0064","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ajmg.a.33909","article-title":"Nosology and classification of genetic skeletal disorders: 2010 revision","volume":"155A","author":"Warman","year":"2011","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.jocd.2019.09.006_bib0065","doi-asserted-by":"crossref","first-page":"5S51","DOI":"10.1016\/S0929-693X(18)30014-9","article-title":"Genetics of hypophosphatasia","volume":"24","author":"Mornet","year":"2017","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.jocd.2019.09.006_bib0066","doi-asserted-by":"crossref","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jocd.2019.09.006_bib0067","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/humu.21636","article-title":"Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias","volume":"33","author":"Foldynova-Trantirkova","year":"2012","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jocd.2019.09.006_bib0068","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1002\/ajmg.a.38349","article-title":"MED resulting from recessively inherited mutations in the gene encoding calcium-activated nucleotidase CANT1","volume":"173","author":"Balasubramanian","year":"2017","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.jocd.2019.09.006_bib0069","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/jhg.2017.56","article-title":"Copy-number variants and candidate gene mutations in isolated split hand\/foot malformation","volume":"62","author":"Carter","year":"2017","journal-title":"J Hum Genet"},{"key":"10.1016\/j.jocd.2019.09.006_bib0070","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0140-6736(07)61090-3","article-title":"Achondroplasia","volume":"370","author":"Horton","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jocd.2019.09.006_bib0071","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(19)31274-7","article-title":"Genomic medicine for undiagnosed diseases","volume":"394","author":"Wise","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jocd.2019.09.006_bib0072","article-title":"Patients' views on variants of uncertain significance across indications","author":"Clift","year":"2019","journal-title":"J Community Genet"},{"key":"10.1016\/j.jocd.2019.09.006_bib0073","unstructured":"Evenity Prescribing Information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761062s000lbl.pdf. Accessed 8 September, 2019."},{"key":"10.1016\/j.jocd.2019.09.006_bib0074","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0075","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2019.09.006_bib0076","unstructured":"Crysvita Prescribing Information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761068s000lbl.pdf. Accessed 8 September, 2019."},{"key":"10.1016\/j.jocd.2019.09.006_bib0077","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/jbmr.3657","article-title":"Diagnosis and management of Paget's disease of bone in adults: a clinical guideline","volume":"34","author":"Ralston","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0078","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: a meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0079","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/jbmr.3355","article-title":"Treatment-related changes in bone turnover and fracture risk reduction in clinical trials of anti-resorptive drugs: a meta-regression","volume":"33","author":"Bauer","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0080","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/jbmr.3722","article-title":"Relationship between bone mineral density t-score and nonvertebral fracture risk over 10 years of denosumab treatment","volume":"34","author":"Ferrari","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0081","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.3039","article-title":"Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis","volume":"32","author":"Cummings","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0082","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2019.09.006_bib0083","first-page":"999","article-title":"Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial","volume":"114","author":"McClung","year":"2009","journal-title":"ObstetGynecol"},{"key":"10.1016\/j.jocd.2019.09.006_bib0084","unstructured":"University of Sheffield. Bisphosphonates 2019, Celebrating 50 years, 15-17 July 2019 - Sheffield, UK. Available at: https:\/\/bisphosphonates2019.org\/. Accessed September 9, 2019."},{"key":"10.1016\/j.jocd.2019.09.006_bib0085","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1002\/jbmr.2202","article-title":"Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011","volume":"29","author":"Solomon","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0086","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11914-009-0006-3","article-title":"Quality health care gaps in osteoporosis: how can patients, providers, and the health system do a better job?","volume":"7","author":"Teng","year":"2009","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.jocd.2019.09.006_bib0087","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00198-004-1680-8","article-title":"Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark","volume":"16","author":"Vestergaard","year":"2005","journal-title":"OsteoporosInt"},{"key":"10.1016\/j.jocd.2019.09.006_bib0088","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/joim.12586","article-title":"Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project","volume":"281","author":"Katsoulis","year":"2017","journal-title":"J Intern Med"},{"key":"10.1016\/j.jocd.2019.09.006_bib0089","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/jbmr.2888","article-title":"A crisis in the treatment of osteoporosis","volume":"31","author":"Khosla","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0090","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s00198-013-2348-z","article-title":"Capture the fracture: a best practice framework and global campaign to break the fragility fracture cycle","volume":"24","author":"Akesson","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.09.006_bib0091","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/jbmr.2180","article-title":"The potential economic benefits of improved postfracture care: a cost-effectiveness analysis of a fracture liaison service in the US health-care system","volume":"29","author":"Solomon","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0092","series-title":"Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis","year":"1994"},{"key":"10.1016\/j.jocd.2019.09.006_bib0093","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","article-title":"Imminent risk of fracture after fracture","volume":"28","author":"Johansson","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.09.006_bib0094","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1001\/jama.1995.03530200014013","article-title":"From the Food and Drug Administration","volume":"274","author":"Nightingale","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2019.09.006_bib0095","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0096","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0097","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0098","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMp1202619","article-title":"Bisphosphonates for osteoporosis - where do we go from here?","volume":"366","author":"Whitaker","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2019.09.006_bib0099","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"Klibanski","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2019.09.006_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00774-007-0793-5","article-title":"Bone quality: the material and structural basis of bone strength","volume":"26","author":"Seeman","year":"2008","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.jocd.2019.09.006_bib0101","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1172\/JCI113523","article-title":"Age and bone mass as predictors of fracture in a prospective study","volume":"81","author":"Hui","year":"1988","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jocd.2019.09.006_bib0102","unstructured":"The Lewin Group. 2007Assessing the costs of performing DXA services in the office-based setting (survey data report prepared for American Association of Clinical Endocrinologists. International Society for Clinical Densitometry, The Endocrine Society, and American College of Rheumatology). Available at: https:\/\/www.aace.com\/files\/dxafinalreport.pdf. Accessed 8 February, 2017."},{"key":"10.1016\/j.jocd.2019.09.006_bib0103","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00198-017-4345-0","article-title":"Hip fracture trends in the United States, 2002 to 2015","volume":"29","author":"Lewiecki","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.09.006_bib0104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jocd.2017.12.001","article-title":"Osteoporosis: heading towards the perfect storm","volume":"21","author":"Hamdy","year":"2018","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2019.09.006_bib0105","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1210\/jc.2017-02656","article-title":"Persistence of excess mortality following individual nonhip fractures: a relative survival analysis","volume":"103","author":"Tran","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2019.09.006_bib0106","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.2009.50","article-title":"Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women","volume":"301","author":"Bliuc","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2019.09.006_bib0107","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1210\/jc.2010-2730","article-title":"Osteoporosis medication and reduced mortality risk in elderly women and men","volume":"96","author":"Center","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2019.09.006_bib0108","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mayocp.2014.09.011","article-title":"Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States","volume":"90","author":"Singer","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jocd.2019.09.006_bib0109","series-title":"Bone Health and Osteoporosis: A Report of the Surgeon General","year":"2004"},{"key":"10.1016\/j.jocd.2019.09.006_bib0110","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrendo.2013.154","article-title":"Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches","volume":"9","author":"Canalis","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jocd.2019.09.006_bib0111","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/jbmr.3143","article-title":"BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial","volume":"32","author":"Glorieux","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0112","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJMoa1106173","article-title":"Enzyme-replacement therapy in life-threatening hypophosphatasia","volume":"366","author":"Whyte","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2019.09.006_bib0113","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician's guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0114","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1172\/JCI72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jocd.2019.09.006_bib0115","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2019.09.006_bib0116","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0117","doi-asserted-by":"crossref","first-page":"e10172","DOI":"10.1002\/jbm4.10172","article-title":"Heterotopic ossification: a comprehensive review","volume":"3","author":"Meyers","year":"2019","journal-title":"JBMR Plus"},{"key":"10.1016\/j.jocd.2019.09.006_bib0118","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/humu.20868","article-title":"Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1","volume":"30","author":"Kaplan","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jocd.2019.09.006_bib0119","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40272-019-00330-0","article-title":"Current and emerging therapeutic options for the management of rare skeletal diseases","volume":"21","author":"Semler","year":"2019","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jocd.2019.09.006_bib0120","series-title":"The RAND\/UCLA Appropriateness Method User's Manual","author":"Fitch","year":"2001"},{"key":"10.1016\/j.jocd.2019.09.006_bib0121","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/01.bpb.0000279021.04000.d3","article-title":"Bone mineral density correlation with fractures in nonambulatory pediatric patients","volume":"27","author":"Khoury","year":"2007","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.jocd.2019.09.006_bib0122","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1359\/jbmr.091007","article-title":"The relationship between fractures and DXA measures of BMD in the distal femur of children and adolescents with cerebral palsy or muscular dystrophy","volume":"25","author":"Henderson","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0123","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/BPO.0b013e3180317403","article-title":"Fractures in patients with cerebral palsy","volume":"27","author":"Presedo","year":"2007","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.jocd.2019.09.006_bib0124","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocd.2019.07.001","article-title":"Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, periprosthetic and orthopedic bone health, transgender medicine, and pediatrics","author":"Shuhart","year":"2019","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2019.09.006_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocd.2019.07.003","article-title":"The Official Positions of the International Society for Clinical Densitometry: Detection of Atypical Femur Fractures","author":"Cheung","year":"2019","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2019.09.006_bib0126","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1302\/0301-620X.99B3.BJJ-2016-0276.R2","article-title":"Atypical femoral fractures related to bisphosphonate treatment: issues and controversies related to their surgical management","volume":"99-B","author":"Koh","year":"2017","journal-title":"Bone Joint J"},{"key":"10.1016\/j.jocd.2019.09.006_bib0127","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00198-016-3798-x","article-title":"Bone loss at the distal femur and proximal tibia in persons with spinal cord injury: imaging approaches, risk of fracture, and potential treatment options","volume":"28","author":"Cirnigliaro","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.09.006_bib0128","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1080\/10790268.2017.1368961","article-title":"Evaluating the efficacy of functional electrical stimulation therapy assisted walking after chronic motor incomplete spinal cord injury: effects on bone biomarkers and bone strength","volume":"40","author":"Craven","year":"2017","journal-title":"J Spinal Cord Med"},{"key":"10.1016\/j.jocd.2019.09.006_bib0129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00198-013-2419-1","article-title":"Exploring the determinants of fracture risk among individuals with spinal cord injury","volume":"25","author":"Lala","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.09.006_bib0130","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.sc.3101725","article-title":"Effect of alendronate on bone mineral density in spinal cord injury patients: a pilot study","volume":"43","author":"Moran de Brito","year":"2005","journal-title":"Spinal Cord"},{"key":"10.1016\/j.jocd.2019.09.006_bib0131","unstructured":"Carven BC, Moreno JC, Adachi J.D., Webber C.E.Knee DXA Protocol. Available at: https:\/\/www.kite-uhn.com\/clinical\/tools\/knee-dxa-protocol. Accessed 7 September, 2019."},{"key":"10.1016\/j.jocd.2019.09.006_bib0132","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s00198-017-4171-4","article-title":"Adverse bone effects of medications used to treat non-skeletal disorders","volume":"28","author":"Watts","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.09.006_bib0133","doi-asserted-by":"crossref","first-page":"75646","DOI":"10.18632\/oncotarget.17980","article-title":"The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation","volume":"8","author":"Cianferotti","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jocd.2019.09.006_bib0134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","article-title":"Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG","volume":"7","author":"Hadji","year":"2017","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.jocd.2019.09.006_bib0135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa1700089","article-title":"Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist","volume":"377","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2019.09.006_bib0136","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/pds.4362","article-title":"Effects of analgesics on bone mineral density: a longitudinal analysis of the prospective SWAN cohort with three-group matching weights","volume":"27","author":"Yoshida","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jocd.2019.09.006_bib0137","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S2213-8587(15)00283-1","article-title":"Type 2 diabetes and the skeleton: new insights into sweet bones","volume":"4","author":"Shanbhogue","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jocd.2019.09.006_bib0138","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1503\/cmaj.080486","article-title":"Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis","volume":"180","author":"Loke","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.jocd.2019.09.006_bib0139","doi-asserted-by":"crossref","first-page":"80","DOI":"10.7326\/L19-0320","article-title":"Fracture risk after initiation of use of canagliflozin","volume":"171","author":"Fralick","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jocd.2019.09.006_bib0140","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/1574886313666180226103408","article-title":"Risks associated with SGLT2 inhibitors: an overview","volume":"13","author":"Singh","year":"2018","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.jocd.2019.09.006_bib0141","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/pds.4406","article-title":"Proton pump inhibitor use and the risk of fractures among an older adult cohort","volume":"27","author":"Harding","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jocd.2019.09.006_bib0142","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jocd.2018.06.008","article-title":"Lower trabecular bone score is associated with the use of proton pump inhibitors","volume":"22","author":"Shin","year":"2019","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2019.09.006_bib0143","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1600-0404.2005.00474.x","article-title":"Epilepsy, osteoporosis and fracture risk - a meta-analysis","volume":"112","author":"Vestergaard","year":"2005","journal-title":"Acta NeurolScand"},{"key":"10.1016\/j.jocd.2019.09.006_bib0144","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00198-018-4420-1","article-title":"Depression and risk of fracture and bone loss: an updated meta-analysis of prospective studies","volume":"29","author":"Wu","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.09.006_bib0145","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/gps.4974","article-title":"Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: a systematic review and meta-analysis","volume":"33","author":"Khanassov","year":"2018","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jocd.2019.09.006_bib0146","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00198-018-4413-0","article-title":"Effect of selective serotonin reuptake inhibitors on bone mineral density: a systematic review and meta-analysis","volume":"29","author":"Zhou","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.09.006_bib0147","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00198-014-2852-9","article-title":"Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy","volume":"26","author":"Ozdemir","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.09.006_bib0148","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fphar.2018.00348","article-title":"Non-vitamin K antagonist oral anticoagulants vs. warfarin at risk of fractures: a systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Gu","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jocd.2019.09.006_bib0149","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s11695-017-2666-x","article-title":"Bariatric surgery and endoluminal procedures: IFSO worldwide survey 2014","volume":"27","author":"Angrisani","year":"2017","journal-title":"Obes Surg"},{"key":"10.1016\/j.jocd.2019.09.006_bib0150","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamasurg.2013.3654","article-title":"The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012","volume":"149","author":"Chang","year":"2014","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jocd.2019.09.006_bib0151","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/jbmr.2226","article-title":"Bone metabolism after bariatric surgery","volume":"29","author":"Yu","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0152","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/jbmr.3371","article-title":"Effects of gastric bypass surgery on bone mass and microarchitecture occur early and particularly impact postmenopausal women","volume":"33","author":"Schafer","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0153","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1210\/jc.2018-01496","article-title":"Longitudinal 5-year evaluation of bone density and microarchitecture after Roux-en-Y gastric bypass surgery","volume":"103","author":"Lindeman","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2019.09.006_bib0154","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/jbmr.3101","article-title":"Fracture risk after bariatric surgery: Roux-en-Y gastric bypass versus adjustable gastric banding","volume":"32","author":"Yu","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0155","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2019.1157","article-title":"Fracture risk after Roux-en-Y gastric bypass vs adjustable gastric banding among medicare beneficiaries","author":"Yu","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jocd.2019.09.006_bib0156","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/sj.ijo.0803040","article-title":"Gastric banding induces negative bone remodelling in the absence of secondary hyperparathyroidism: potential role of serum C telopeptides for follow-up","volume":"29","author":"Giusti","year":"2005","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.jocd.2019.09.006_bib0157","doi-asserted-by":"crossref","first-page":"i3794","DOI":"10.1136\/bmj.i3794","article-title":"Change in fracture risk and fracture pattern after bariatric surgery: nested case-control study","volume":"354","author":"Rousseau","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jocd.2019.09.006_bib0158","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bone.2016.11.014","article-title":"Effects of Roux-en-Y gastric bypass and sleeve gastrectomy on bone mineral density and marrow adipose tissue","volume":"95","author":"Bredella","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2019.09.006_bib0159","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1210\/jc.2014-3367","article-title":"Sclerostin levels and changes in bone metabolism after bariatric surgery","volume":"100","author":"Muschitz","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2019.09.006_bib0160","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/jbmr.2467","article-title":"Intestinal calcium absorption decreases dramatically after gastric bypass surgery despite optimization of vitamin D status","volume":"30","author":"Schafer","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0161","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/jbmr.2707","article-title":"The impact of vitamin D, calcium, protein supplementation, and physical exercise on bone metabolism after bariatric surgery: the BABS study","volume":"31","author":"Muschitz","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.09.006_bib0162","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4158\/EP12437.GL","volume":"19","author":"Mechanick","year":"2013","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jocd.2019.09.006_bib0163","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMoa1009370","article-title":"Outcomes of treatment for hepatitis C virus infection by primary care providers","volume":"364","author":"Arora","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2019.09.006_bib0164","unstructured":"Project ECHO at University of New Mexico School of Medicine. 2019ECHO hubs: global. Available at: https:\/\/echo.unm.edu\/locations\/global. Accessed 2 May, 2019."},{"key":"10.1016\/j.jocd.2019.09.006_bib0165","unstructured":"U.S. Department of Health and Human Services. 2019Report to Congress: Current State of Technology-Enabled Collaborative Learning and Capacity Building Models. Available at: https:\/\/aspe.hhs.gov\/system\/files\/pdf\/260691\/ECHOAct-ConsolidatedReportToCongress.pdf. Accessed 21 April, 2019."},{"key":"10.1016\/j.jocd.2019.09.006_bib0166","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00198-016-3708-2","article-title":"Telementoring: a novel approach to reducing the osteoporosis treatment gap","volume":"28","author":"Lewiecki","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.09.006_bib0167","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1210\/js.2017-00361","article-title":"Leveraging scarce resources with bone health TeleECHO to improve the care of osteoporosis","volume":"1","author":"Lewiecki","year":"2017","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.jocd.2019.09.006_bib0168","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.rdc.2019.01.003","article-title":"Project ECHO: telehealth to expand capacity to deliver best practice medical care","volume":"45","author":"Lewiecki","year":"2019","journal-title":"Rheum Dis Clin North Am"}],"container-title":["Journal of Clinical Densitometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695019301957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695019301957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:42:37Z","timestamp":1761082957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094695019301957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":168,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1094695019301957"],"URL":"https:\/\/doi.org\/10.1016\/j.jocd.2019.09.006","relation":{},"ISSN":["1094-6950"],"issn-type":[{"value":"1094-6950","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proceedings of the 2019 Santa Fe Bone Symposium: New Concepts in the Care of Osteoporosis and Rare Bone Diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Densitometry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocd.2019.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The International Society for Clinical Densitometry. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}